What is the price target for IMCR stock?
23 analysts have analysed IMCR and the average price target is 69.3 USD. This implies a price increase of 124.7% is expected in the next year compared to the current price of 30.84.
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Forecast, Price Target & Analyst Ratings
NASDAQ:IMCR • US45258D1054
Current stock price
30.84 USD
-0.02 (-0.06%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMUNOCORE HOLDINGS PLC-ADR (IMCR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.25
- Revenue Estimate
- 109.9M
Price Target Details & History
Consensus Price Target and Range
Mean target
$69.30
Upside
+ 124.70%
From current price of $30.84 to mean target of $69.30, Based on 23 analyst forecasts
Low
$37.37
Median
$69.36
High
$105.00
Price Target Revisions
1 Month
0.18%
3 Months
0.30%
Price Target Summary
23 Wall Street analysts provided a forecast for the next 12 months for IMCR. The average price target is 69.3 USD. This implies a price increase of 124.7% is expected in the next year compared to the current price of 30.84.
The average price target has been revised upward by 0.3% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.48%
IMCR was analyzed by 23 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IMCR.
In the previous month the buy percentage consensus was at a similar level.
IMCR was analyzed by 23 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-16 | Jefferies | Downgrade | Buy -> Hold |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-31 | Wells Fargo | Initiate | Overweight |
| 2025-10-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-04-07 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-03-12 | Needham | Reiterate | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Needham | Reiterate | Buy -> Buy |
| 2025-01-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Needham | Reiterate | Buy -> Buy |
| 2024-12-13 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-11-11 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-11-07 | Needham | Maintains | Buy -> Buy |
| 2024-10-24 | UBS | Initiate | Sell |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-10-07 | Guggenheim | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.25
- Revenue Estimate
- 109.9M
- Revenue Q2Q
- 17.06%
- EPS Q2Q
- -347.86%
- Number of Analysts
- 14
Next Earnings Revisions
Revenue (1 Month)
-2.29%
Revenue (3 Months)
-2.29%
EPS (1 Month)
-49.54%
EPS (3 Months)
-27.89%
Next Earnings Summary
IMCR is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.25 USD and the consensus revenue estimate is 109.90M USD.
The next earnings revenue estimate has been revised downward by 2.29% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 249.428M 73.58% | 310.202M 24.37% | 400.016M 28.95% | 457.57M 14.39% | 495.04M 8.19% | 598.83M 20.97% | 818.46M 36.68% | 1.056B 29.02% | 1.211B 14.68% | 1.446B 19.41% | 1.555B 7.54% | |
| EBITDA YoY % growth | -55.559M -58.88% | -66.257M -19.26% | -42.087M 36.48% | -65.765M -56.26% | -72.052M -9.56% | 7.488M 110.39% | 209.41M 2,696.61% | 341.7M 63.17% | 218.38M -36.09% | 378.83M 73.47% | 568.96M 50.19% | |
| EBIT YoY % growth | -59.649M -45.13% | -70.461M -18.13% | -45.353M 35.63% | -64.289M -41.75% | -47.732M 25.75% | 58.09M 221.70% | 174.75M 200.83% | 376.38M 115.38% | 551.21M 46.45% | 781.07M 41.70% | 910.76M 16.60% | |
| Operating Margin | -23.91% | -22.71% | -11.34% | -14.05% | -9.64% | 9.70% | 21.35% | 35.64% | 45.52% | 54.02% | 58.57% | |
| EPS YoY % growth | -1.14 2.29% | -1.02 10.35% | -0.70 31.37% | -1.08 -53.80% | -1.26 -17.00% | 0.65 151.69% | 2.99 359.25% | 6.30 110.86% | 7.71 22.35% | 10.66 38.18% | 11.48 7.69% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.25 -347.86% | -0.24 -22.40% | -0.16 | -0.29 51.43% | -0.38 -51.85% | -0.39 -60.42% | -0.42 -166.24% | -0.44 -51.20% |
| Revenue Q2Q % growth | 109.9M 17.06% | 112.81M 15.15% | 116.49M 12.34% | 118.62M 13.54% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -20.323M -635.80% | -17.084M -29.03% | -19.651M -314.67% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.919M -340.23% | -13.559M 8.85% | -6.95M 3.08% | -9.141M 53.58% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
43.10%
EPS Next 5 Year
61.56%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.41%
Revenue Next 5 Year
20.80%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
29.62%
EBIT Next 5 Year
58.86%
IMMUNOCORE HOLDINGS PLC-ADR / IMCR Forecast FAQ
What is the next earnings date for IMCR stock?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) will report earnings on 2026-05-05, before the market open.
What are the consensus estimates for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) next earnings?
The consensus EPS estimate for the next earnings of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is -0.25 USD and the consensus revenue estimate is 109.90M USD.
What is the consensus rating for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
The consensus rating for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is 83.4783 / 100 . This indicates that analysts generally have a positive outlook on the stock.